Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials – The Lancet (link to abstract – $ for full-text)   Commentary on Twitter For refractory chronic cough or unexplained chronic cough, gefapixant 45 mg twice […]

The post RCT: Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough. appeared first on Links Medicus.